TrialJournal for immunotherapy of cancer2022

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.

Ahmad A Tarhini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.